NRIX — Nurix Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1549595 ·
Last close
$14.24
Market Cap
$1.56B
52W High
$28.23
52W Low
$12.43
ADV30
3,578,968
Next earnings
2027-01-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Aug 2026 | 673,064,000 | — | 559,451,000 | 549,807,000 | 1,195,298,000 | 720,242,000 | 226,987,000 |
| May 2026 | 9,043,000 | — | -94,204,000 | -89,535,000 | 535,540,000 | 67,685,000 | 132,913,000 |
| Feb 2026 | 6,252,000 | — | -92,495,000 | -87,174,000 | 636,130,000 | 71,195,000 | 155,237,000 |
| Nov 2025 | 13,577,000 | — | -83,095,000 | -78,221,000 | 688,135,000 | 246,960,000 | 149,388,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-293,704,000
Investing CF
$19,992,000
Financing CF
$257,204,000
CapEx
$-10,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-10-17
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,179,935,000
Inventory
—
Receivables
$19,000,000
ST Investments
$375,844,000
EBIT TTM
$-361,179,000
Pretax Income TTM
$-341,622,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$701,936,000
EBITDA
$297,767,008
Free Cash Flow
$233,337,632
Enterprise Value
$1,684,957,440
Total Cash
$1,048,254,976
Total Debt
$65,332,000
Shares Out
109,249,814
Trailing EPS
$2.38
Book Value
$8.87
ROE
44.0%
ROA
21.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 83,980,000 | -285,666,000 | -264,457,000 | 688,135,000 | 149,388,000 | 538,747,000 | -249,465,000 |
| Nov 2024 | 54,549,000 | -213,027,000 | -193,569,000 | 669,343,000 | 142,350,000 | 526,993,000 | -172,584,000 |
| Nov 2023 | 76,987,000 | -155,063,000 | -143,948,000 | 355,598,000 | 155,105,000 | 200,493,000 | -81,365,000 |
| Nov 2022 | 38,627,000 | -183,867,000 | -180,360,000 | 416,759,000 | 113,063,000 | 303,696,000 | -159,807,000 |
TTM Snapshot
Revenues TTM
$36,766,000
NetIncome TTM
$-341,351,000
OpCashFlow TTM
—
Assets (Latest)
$535,540,000
Forward EPS
$-1.28
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $26.00 · spot: $14.10 · call volume: 437 · put volume: 895Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.58B | $14.77 | — |
| KLRA | Kailera Therapeutics, Inc. | $1.58B | $12.20 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.59B | $69.99 | — |
News headlines (Yahoo Finance, 1h cache)
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
2026-11-11 12:00 · Yahoo
Nurix Therapeutics to Participate in Upcoming Investor Conferences
2026-11-10 12:00 · Yahoo
Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
2026-11-07 06:12 · Yahoo
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
2026-11-05 12:00 · Yahoo
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
2026-11-04 21:19 · Yahoo
NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
2026-11-04 21:14 · Yahoo
Sanofi (ENXTPA:SAN) Drops SAR448272 And Backs New Immunology Candidate
2026-11-04 19:14 · Yahoo
Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme
2026-11-04 13:47 · Yahoo
NRIX Slumps 35% After-Hours — What’s Driving The Selloff?
2026-11-03 22:58 · Yahoo
Nurix Therapeutics stock tumbles on Sanofi program termination
2026-11-03 21:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.